Alimera Sciences Overview
Ticker: ALIM
Current Price: $6.10
Market Cap: $29 million
Bullets:
*Focused on Retinal Disease
*Diabetic Macular Edema(DME) is leading cause of vision loss in diabetic patients.
*Product 'Iluvien" - continuous micro-dosing to the eye for patients
*Company launching selected markets worldwide
*2019 Revenues = $53.9 mm (Up 16% from 2018)
*1st Qtr 2020 revenues up 12% vs. same period in '19
*$12 million cash as of 3/31/2020
Background:
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.
www.alimerasciences.com.
Market Data 
Markets 
AI
